Navigation Links
Interleukin Genetics Retains Top Life Science Communications Firms
Date:3/18/2008

Stern Investor Relations and LaVoie Group Selected as IR, PR Agencies of

Record

WALTHAM, Mass., March 18 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc., (Amex: ILI), announced today that it has retained two premier life science communications firms, Stern Investor Relations, Inc., and LaVoie Group, as agencies of record to provide investor relations and public relations services, respectively.

The two firms will provide strategic counsel and execution, will lead efforts to communicate Interleukin Genetics' vision to use the science of applied genetics to personalize health management and will support the Company's strategy to establish additional partnerships and relationships with biotechnology and pharmaceutical companies.

Lewis H. Bender, Chief Executive Officer commented, "Interleukin Genetics has a strong message on the value of diagnostic testing to empower consumers to personalize their health. With the addition of these two firms, I am confident that we will deliver our message more effectively to our key constituencies."

About LaVoie Group

LaVoie Group provides strategic, integrated marketing and communications- including marketing strategy, corporate communications, as well as public and investor relations to life sciences and healthcare companies. LaVoie Group's clients range from start-ups to industry leaders. For more information, visit http://www.lavoiegroup.com.

About Stern Investor Relations

Stern Investor Relations provides investor relations consulting services to biotechnology and healthcare companies. Stern IR develops and implements strategic investor relations programs design
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
2. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
3. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
4. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
5. Interleukin Genetics Announces Management and Board Appointments
6. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
7. deCODE Genetics Announces Full-year 2007 Financial Results
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
10. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
11. Smart Genetics Announces Plans to Launch a New Alzheimers Risk Assessment Service

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...HealthRoboticstodayannounced,thatithasformedanewCa...hisrecentlyformedToronto-basedcompanywilloperateun...install,andsupport,HealthRobotics,i.v.RoomoftheFut...feringsi.v.STATION(TM),i.v.SOFT(TM),andOMM(TM).,He...n"asneeded,basis"toitsstrategicpartnershipswithMcK...
(Date:11/24/2009)...--CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CTIC)man...hCareConference.TheconferencewillbeheldDecember1-2...tonTuesday,December1at11:00a.m.EasternTimeinHolmes...llbeavailableat www.celltherapeutics.com ,anditwil...rayHealthCareConference,NewYorkPalaceHotel,Holmes1...
(Date:11/23/2009)...unication, computation and more powerful ways to e...antum states as carriers of information is an extr...hown, mathematically, how to gently tease out unwa... the information intact. Their work is reported in...d highlighted with a Viewpoint in Physics ( http...
(Date:11/23/2009)...stCall/-YMBioSciencesInc.(NYSEAmex: YMI ;TSX:YM),a...sandadvancesadiverseportfolioofpromisingcancer-rel...rtedthatCytopia(ASX:CYT)hascommencedenrollmentofaP...isteredJAK1/JAK2inhibitor.Thetrialisbeingconducted...CytopiaintoYMhasbeenpreviouslyannouncedandispendin...
Breaking Biology Technology:Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4
...d leader in,the rapidly evolving field of cancer m...appointed Hessel J. H. M. Lindenbergh as Chairman ... former member of the managing board of ING,Group ...e supervisory board,of NIB Capital N.V. and board ...l and Gamma Holding. Mr. Lindenbergh is also a mem...
...ls,Inc. (Amex: ANX ), a biopharmaceutical researc...ng proprietary product candidates for the treatmen...ay that Evan M. Levine,ADVENTRX,s chief executive ...y Partners, Fifth Annual Growth Conference on Wedn...ylight Time, 5:30pm Eastern,Daylight Time. The con...
...- Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , ...urable decision from the Intellectual Property Off... & Johnson,s subsidiary, Conor Medsystems,Inc. ("C...3799, which,pertains to compositions comprising a ...aclitaxel-eluting stents. In a decision dated Sept...
Other Biology Technology:Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board 2ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 2Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 3Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 4
(Date:11/23/2009)...INCINNATINew research presents strong evidence tha...to both outdoor traffic-related pollution and indo...than one or the other exposure alone. , Enviro...cinnati (UC) College of Medicine have shown that c...ated particles and indoor endotoxin during early l...
(Date:11/23/2009)... A new study by the Wildlife Conservation Society ...ge swamp in the Republic of Congopart of the "moth...last yearare becoming increasingly threatened by g...y recommends protection of the swamp forests adjac...serve after recent surveys confirmed that high den...
(Date:11/23/2009)... AMES, Iowa - The only swine vaccine available for... herd infected with the virus. The vaccination mar... herd diagnosed with the pandemic flu., Iowa Sta...cience, developed the vaccine this summer and has ...in Iowa, Kansas and Illinois for several weeks., ...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Eli Lilly 26 Company and ScinoPharm Taiwan Ltd Announce Settlement of Gemcitabine Litigation 13272 1Eli Lilly 26 Company and ScinoPharm Taiwan Ltd Announce Settlement of Gemcitabine Litigation 13272 2Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 1Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 2Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 3Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 4Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 5Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 6Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 7Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 8Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 9Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 10Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 11Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 12Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 13Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 14Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 15Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 16Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 17Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 18Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 1Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 2Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 3Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 4Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 5Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 6Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 7Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 8Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 9Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 10Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 11Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 12Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 13Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 14Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 15Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 16Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 17Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 18Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 19Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 20Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 21Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 22Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 23Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 24Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 25Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 26Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 27Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 28Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 29
..., 115 scientists from around the world report in t...ne" of data on a tiny green alga called Chlamydomo...single-celled Chlamydomonas, a slimy organism that... genes, and scientists now know 95 percent of the ...ew less than 2 percent. , "It,s like having a dic...
...nia have discovered that the nuclei of human stem ...han hard, making it easier for stem cells to migra... but ultimately to put human genes in the correct ...Researchers pulled cell nuclei into microscopic gl...d the shear of the DNA and associated proteins by ...
...Energys Office of Science today released a compreh...cilities for the Future of Science: A Twenty-Year ...t progress in deploying the scientific facilities ...pture world scientific leadership, extend the fron...ons. , When it was published four years ago, the ...
Other Biology News:Study involving more than 100 scientists provides new insights on green algae 2Study involving more than 100 scientists provides new insights on green algae 3Study involving more than 100 scientists provides new insights on green algae 4Stem cell nuclei are soft 'hard drives,' Penn study finds 2DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 2DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 3DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 4DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 5
Mouse Anti-Cytokeratin 5 / 14 Monoclonal Antibody, Unconjugated, Clone LH8 from Abcam
Rabbit Anti-Human C1QC Polyclonal Antibody, Unconjugated from Atlas Antibodies
Mouse Anti-Human Integrin alpha 2b / beta 3 Monoclonal Antibody, Unconjugated, Clone CRC64 from Abcam
Rabbit Anti-NCoR2 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: